Subject
Virology,Infectious Diseases,Immunology,Epidemiology
Reference5 articles.
1. Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV 8: e185–96.
2. Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials;Rizzardini;J Acquir Immune Defic Syndr,2020
3. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection;Segal-Maurer;N Engl J Med,2022
4. Lenacapavir administered every 6 months or daily in combination with daily oral antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial;Gupta;Lancet HIV,2023
5. Correll T et al. Total lymphocyte and lymphocyte subset changes in participants receiving islatravir (0.25, 0.75 and 2.25mg QD) and doravirine (DOR) +/- lamivudine (3TC): post-hoc analysis from a phase 2b dose-ranging study (P011). International Congress on Drug Therapy in HIV Infection (HIV Glasgow); Oc2 23–26, 2022 (abstr O46).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献